Bitcoin groundbreakers share personal stories of how Bitcoin is changing lives for the better. Host Mauricio Di Bartolomeo, co-founder and CSO of Ledn, speaks with leading Bitcoin voices, entrepreneurs, and human rights advocates to hear their unique journey and practical real-world examples of how Bitcoin has made a positive impact in their lives. Brought to you by Ledn, a leading financial services company built for Bitcoin & digital assets. Ledn offers a suite of lending, saving and tradi ...
…
continue reading
Inhalt bereitgestellt von Proactive Investors. Alle Podcast-Inhalte, einschließlich Episoden, Grafiken und Podcast-Beschreibungen, werden direkt von Proactive Investors oder seinem Podcast-Plattformpartner hochgeladen und bereitgestellt. Wenn Sie glauben, dass jemand Ihr urheberrechtlich geschütztes Werk ohne Ihre Erlaubnis nutzt, können Sie dem hier beschriebenen Verfahren folgen https://de.player.fm/legal.
Player FM - Podcast-App
Gehen Sie mit der App Player FM offline!
Gehen Sie mit der App Player FM offline!
Tryptamine Therapeutics raises $6 million to accelerate development of TRP-8803
MP3•Episode-Home
Manage episode 447532132 series 2891889
Inhalt bereitgestellt von Proactive Investors. Alle Podcast-Inhalte, einschließlich Episoden, Grafiken und Podcast-Beschreibungen, werden direkt von Proactive Investors oder seinem Podcast-Plattformpartner hochgeladen und bereitgestellt. Wenn Sie glauben, dass jemand Ihr urheberrechtlich geschütztes Werk ohne Ihre Erlaubnis nutzt, können Sie dem hier beschriebenen Verfahren folgen https://de.player.fm/legal.
Tryptamine Therapeutics Ltd (ASX: TYP) CEO Jason Carroll joins Proactive’s Tylah Tully to talk through $6 million the company has secured through a strategic placement of 300 million new shares at $0.02 each. The placement was supported by new and existing stakeholders, including cornerstone investors, the Merchant Biotech Fund and Dr Daniel Tillett, who will join the board as a non-executive director. Key shareholders and company executives, including Carroll himself, also participated. The funds will facilitate the accelerated clinical development of TRP-8803, an IV-infused psilocin formulation designed to address limitations associated with oral psilocybin dosing. Benefits of TRP-8803 include faster onset, more controlled dosing and shorter intervention times. This aligns with Tryp’s ongoing efforts to explore the compound’s therapeutic potential in treating various conditions. The recent Phase 1b study confirmed TRP-8803’s safety, bolstering plans for larger trials and potential product registration in Australia. The placement, scheduled in two tranches, will enable Tryp to advance its clinical strategy. Merchant Group acted as lead manager for the placement, with shareholder approvals anticipated for tranche two in an upcoming General Meeting. #ProactiveInvestors #TrypTherapeutics #ASX #ClinicalTrials, #Psilocin, #PsychedelicTherapy, #TRP8803, #Psilocybin, #MentalHealth, #BiotechNews, #Pharmaceuticals, #HealthInnovation, #MedicalResearch, #BiotechFunding, #ASXNews, #PsychiatricDisorders, #Investment, #BioPharma, #MedicalTrials, #DrugDevelopment, #IVTherapy, #HealthSolutions
…
continue reading
613 Episoden
MP3•Episode-Home
Manage episode 447532132 series 2891889
Inhalt bereitgestellt von Proactive Investors. Alle Podcast-Inhalte, einschließlich Episoden, Grafiken und Podcast-Beschreibungen, werden direkt von Proactive Investors oder seinem Podcast-Plattformpartner hochgeladen und bereitgestellt. Wenn Sie glauben, dass jemand Ihr urheberrechtlich geschütztes Werk ohne Ihre Erlaubnis nutzt, können Sie dem hier beschriebenen Verfahren folgen https://de.player.fm/legal.
Tryptamine Therapeutics Ltd (ASX: TYP) CEO Jason Carroll joins Proactive’s Tylah Tully to talk through $6 million the company has secured through a strategic placement of 300 million new shares at $0.02 each. The placement was supported by new and existing stakeholders, including cornerstone investors, the Merchant Biotech Fund and Dr Daniel Tillett, who will join the board as a non-executive director. Key shareholders and company executives, including Carroll himself, also participated. The funds will facilitate the accelerated clinical development of TRP-8803, an IV-infused psilocin formulation designed to address limitations associated with oral psilocybin dosing. Benefits of TRP-8803 include faster onset, more controlled dosing and shorter intervention times. This aligns with Tryp’s ongoing efforts to explore the compound’s therapeutic potential in treating various conditions. The recent Phase 1b study confirmed TRP-8803’s safety, bolstering plans for larger trials and potential product registration in Australia. The placement, scheduled in two tranches, will enable Tryp to advance its clinical strategy. Merchant Group acted as lead manager for the placement, with shareholder approvals anticipated for tranche two in an upcoming General Meeting. #ProactiveInvestors #TrypTherapeutics #ASX #ClinicalTrials, #Psilocin, #PsychedelicTherapy, #TRP8803, #Psilocybin, #MentalHealth, #BiotechNews, #Pharmaceuticals, #HealthInnovation, #MedicalResearch, #BiotechFunding, #ASXNews, #PsychiatricDisorders, #Investment, #BioPharma, #MedicalTrials, #DrugDevelopment, #IVTherapy, #HealthSolutions
…
continue reading
613 Episoden
Alle Folgen
×Willkommen auf Player FM!
Player FM scannt gerade das Web nach Podcasts mit hoher Qualität, die du genießen kannst. Es ist die beste Podcast-App und funktioniert auf Android, iPhone und im Web. Melde dich an, um Abos geräteübergreifend zu synchronisieren.